Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli. This decision occurred against a backdrop of significant market volatility, ...

Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 5.2% in the afternoon session after stocks rebounded, ...

RBC Capital analyst Conor McNamara initiated coverage of Natera (NTRA) with an Outperform rating and $251 price target The firm says Natera is ...

Q4 2024 Earnings Call Transcript February 28, 2025 Operator: Welcome everyone to Natera’s 2024 Fourth Quarter Financial ...

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish ...

Natera has a twelve month low of $83.13 and a twelve month high of $183.00. The stock has a 50-day simple moving average of $165.61 and a two-hundred day simple moving average of $148.09.

We had a strong finish to the year, with excellent performance across the board,” said Steve Chapman, chief executive officer ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical trial. HEROES is a multi-center ...

AUSTIN, Texas - Natera, Inc. (NASDAQ: NTRA), a healthcare diagnostics company with impressive revenue growth of 57% over the last twelve months and a market capitalization of $19 billion ...

HEROES is Natera's first clinical trial using Signatera to guide de-escalation of therapy in patients with metastatic HER2+ breast cancer Approximately 170 patients are expected to enroll in up ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the U.S. Patent and Trademark Office has issued Natera a new patent related to testing of ...